samedan logo
 
 
spacer
home > pmps > autumn 2020 > the future of the pharma ecosystem post-covid-19
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Future of the Pharma Ecosystem Post-COVID-19

The ongoing global pandemic has caused complete upheaval across the world for individuals and businesses alike. Within the pharmaceutical and life science industry, the need to develop a vaccine quickly is putting immense pressure on a workforce that is arguably already stretched, as skills shortages continue to have an effect on resources. However, while the pandemic has certainly presented a number of challenges, it has also created opportunities that have the potential to help alleviate many long-standing recruitment barriers.

So, what impact has COVID-19 had on talent acquisition across the life science and pharma industry?

A Changing Talent Landscape

STEM skills shortages have been widely discussed for some time now, and anyone in the pharma or life science arena will certainly be acutely aware of the talent challenges facing almost every firm in the field. The simple truth is that following a career in STEM-related professions doesn’t appeal to enough individuals in education to ensure a steady stream of newly trained recruits to meet demand on a global scale. With digital skills in limited supply, but high demand across almost every sector, attracting tech talent into pharma and the life science industry isn’t easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jim Sykes has 20 years’ experience in talent acquisition and holds significant international experience, having supported clients and managed teams on a global basis. He is responsible for client relationships and delivery within the pharma and life science sector and the professional and business services sector at Alexander Mann Solutions.
spacer
Jim Sykes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Emmes launches Orphan Reach™: Emmes’ Rare Disease Center

03rd November, 2021, Rockville, Maryland (USA): Emmes – a full service, global clinical research organization (CRO) – is launching its new center, Orphan Reach™ as a unique ‘rare CRO’.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement